The time frame is one of the reasons I thought we would hit that Double-oughtober target, both a UK and a US approval. I was really disappointed when UK approval wasn't announced in our Breaking News presentation.
Little guys aren't supposed to do what our management team and our drug are doing. This is a real paradigm shift.
I really hope that Clinigen comes through with significant results based on Compassionate Use. They are extremely well-positioned for lenzilumab's market penetration in Europe.
On a different, and unpopular, subject, we had Price Change Parity with CYDY at -$0.02 at 9:53 Eastern. I didn't post it because it was early, and I wanted to see if it was just noise.
But it does appear to be working with support and/or resistance at $6.58 for HGEN, and $1.49 for CYDY.
Regardless, I totally understand your frustration, and I, too, will continue to wait. I still have one small sell order placed in the low $6B market cap range. Novavax has gotten beaten up, but they're still at a $10B market cap, which is less than half of what it was after their early success was announced.
Market Data 
Markets 
AI
